DiaGenic ASA: DiaGenic Reports AMYtect™ Study Results
OSLO, Norway--(BUSINESS WIRE)--Regulatory News:
DiaGenic (OSE:DIAG) reports final results from an exploratory study that examines the agreement between gene expression in blood and brain amyloid PET imaging. In a patient population of 144 patients, a gene expression biomarker was identified that demonstrated an agreement of 69% with brain amyloid PET imaging.
Help employers find you! Check out all the jobs and post your resume.